knowledge -WSS

knowledge

author：Wikipedia 2025-10-06 17:47:56 - browse：7

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： What drug price negotiations mean for Medicare Part D

WSS

Why Novartis is changing the name of its research labs

NYU Langone launches private ChatGPT for its health care data

What do new weight loss drugs mean for bariatric surgery?

How to fix cancer clinical trials' diversity problem

FDA panel gives mixed vote on blood pressure devices

Radiation, mainstay of cancer treatment, begins a fade

explore

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Neuroscience startup Neumora files for IPO

Medical leaders decry Supreme Court decision on affirmative action

Crinetics acromegaly drug succeeds in late

Virginia high school admissions case could be legal follow

AstraZeneca challenges Medicare drug negotiation program

Hollywood unions extend contract negotiations for actors

Australia’s approach to dialysis celebrates life

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicaid rebukes states for mistakenly disenrolling children

leisure time

What AAP's gender

Stem cell treatment guidelines are released by FDA

How to make Best Hospitals ratings actually useful for patients

Covid hospitalizations on the rise, Humana says

Medicaid rebukes states for mistakenly disenrolling children

What drug price negotiations mean for Medicare Part D

entertainment

focus

leisure time

leisure time